NCT05024994View on ClinicalTrials.gov

A Study of E7820 in People With Bone Marrow (Myeloid) Cancers

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 13, 2021

Primary Completion Date

June 19, 2025

Study Completion Date

June 19, 2025

Conditions
Acute Myeloid LeukemiaMyelodysplastic SyndromesChronic Myelomonocytic Leukemia
Interventions
DRUG

E7820

100mg of E7820 QD

Trial Locations (7)

10604

Memorial Sloan Kettering Westchester (All protocol activities), Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Commack, Commack

33136

University of Miami (Data Collection AND Specimen Analysis Only), Miami

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

All Listed Sponsors
collaborator

Eisai Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT05024994 - A Study of E7820 in People With Bone Marrow (Myeloid) Cancers | Biotech Hunter | Biotech Hunter